ACTRN12623000634673尚未招募Unknown
Evaluating glucose control using a next generation automated insulin delivery algorithm in patients with type 1 and type 2 diabetes: Phase 4
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Age at time of consent 16+ years
- •2. Individuals must be diagnosed with type 1 diabetes based on investigator’s clinical judgment for at least 1 year. Individuals diagnosed with type 2 diabetes must be on basal and bolus insulin therapy, with no specified duration.
- •3. A1C between 7.5-11.0% at screening
- •4. Currently using U-100 rapid-acting insulin analogs with insulin pump or receiving multiple daily injections suitable for conversion to pump therapy for at least 3 months prior to study start
- •5. Willing to use a Dexcom G6 CGM for the duration of the study
- •6. Willing to use the Omnipod® 5 Automated Insulin Delivery System during the study
- •7. Willing to perform all fingerstick BG testing with their personal blood glucose meter at the frequency specified in the study protocol or per investigator discretion
- •8. Willing to use carbohydrate counting for determination of meal boluses
- •9. Willing and able to sign the Informed Consent Form (ICF) and/or has a parent/guardian willing and able to sign the ICF.
排除标准
- •1. Any medical condition, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal failure, eating disorders, or other conditions which in the opinion of the investigator, would put the participant at an unacceptable safety risk
- •2. Blood disorder or dyscrasia within 3 months prior to screening, including the use of hydroxyurea, which in the investigator’s opinion could interfere with determination of HbA1C.
- •3. History of severe hypoglycemia within the past 6 months
- •4. History of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome in the past 6 months, unrelated to an intercurrent illness or infusion set failure
- •5. History of moderate to severe preproliferative or proliferative retinopathy based on screening within the last 12 months.
- •6. Planning to start a non-insulin anti-diabetic medication during the study. If on non-insulin medication, dose must be stable in the previous 30 days.
- •7. Planning to start a weight-loss agent during the study. If on a weight-loss medication, dose must be stable in the previous 30 days.
- •8. Currently on a low carbohydrate diet of < 60 grams of carbohydrates per day
- •9. Pregnant, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilisation such as tubal ligation or hysterectomy, or vasectomised partner)
- •10. Dermatological conditions at the proposed sensor/pump wear sites that in the investigator’s opinion could preclude ability to wear the Pod and/or the Dexcom sensor
- •11. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12 months.
- •12. Currently on systemic steroids or intends to receive systemic steroid treatment in the next 6 months, including stable treatment for adrenal insufficiency. Inhaled, ophthalmic, topical, joint injection, and other locally applied steroids are allowed.
- •13. Currently participating in another clinical study using an investigational drug or device
- •14. Recent (within the preceding 30 days) participation in a clinical study using an investigational drug
- •15. Unable to follow the clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator’s clinical judgment
研究者
相似试验
已完成
Unknown
EVOLUTION trial (EValuating glucose contrOL Using a next generaTION automated insulin delivery algorithm in patients with type 1 and type 2 diabetes: EVOLUTION)Type 2 diabetes mellitusMetabolic and Endocrine - DiabetesType 1 diabetes mellitusACTRN12623000623695niversity of Otago20
尚未招募
不适用
Hybrid Closed Loop in Advanced Renal DiseaseEnd stage renal diseaseCKD IIIB-IVMetabolic and Endocrine - DiabetesRenal and Urogenital - Kidney diseaseType 1 DiabetesType 2 DiabetesACTRN12622000889752St Vincent's Hospital Mebourne40
已完成
不适用
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 DiabetesDiabetes MellitusNCT06181721Insulet Corporation20
招募中
4 期
Pilot study to evaluate glycemic control using GlucoTab in combination with continuous glucose monitoring in non-critically ill patients with type 2 diabetes at the general wardE11Type 2 diabetes mellitusDRKS00030400Medizinische Universität Graz30
已完成
Unknown
Continuous glucose monitoring (CGM) in advanced neurodegenerative diseasesneurodegenerative diseases0JPRN-jRCT1090220372ational Health Organization Hyogo-Chuo National Hospital10